NO972930L - Fibronectin-adhesjonsinhibitorer - Google Patents

Fibronectin-adhesjonsinhibitorer

Info

Publication number
NO972930L
NO972930L NO972930A NO972930A NO972930L NO 972930 L NO972930 L NO 972930L NO 972930 A NO972930 A NO 972930A NO 972930 A NO972930 A NO 972930A NO 972930 L NO972930 L NO 972930L
Authority
NO
Norway
Prior art keywords
amino acid
acid selected
fibronectin
terminus
linker
Prior art date
Application number
NO972930A
Other languages
English (en)
Other versions
NO972930D0 (no
Inventor
Anand Swaroop Dutta
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426254.0A external-priority patent/GB9426254D0/en
Priority claimed from GBGB9505905.1A external-priority patent/GB9505905D0/en
Priority claimed from GBGB9513904.4A external-priority patent/GB9513904D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO972930D0 publication Critical patent/NO972930D0/no
Publication of NO972930L publication Critical patent/NO972930L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives cykliske peptider med formel (1) >-.AA1-AA2-AA3-AA'^ LINKER' (1) hvor AA1 er en L- eller ^-aminosyre valgt fra Ile ogLeu eller en aminosyreanalog derav, AA2 er en L-aminosyre valgl fra Lau eller en aminosyreanalog derav, AA3 er en L-aminosyre valgt fra Asp eller en aminosyreanalog cderav, som i sin sidekjede inneholderen karboksylgruppe; AA4 er en L-aminosyre valgt fra Val eller en aminosyreanalog derav, og; LINKER representerer en sammenkoblende del for å koble N-enden av AA1 til C- enden av AA4 under dannelse av et cyklisk peptid som inneholder en heterocyklisk ring som har 17 til 30 ledd. De cykliske peptidene inhiberer interaksjonen mellom VCAM-1 (Vascular Cell Adhesion Molecule-1) og fibronectin, med integrinet VLA-4 (Very Late Antigen 4) og har terapeutiske anvendelser, f eks. ved reumatoid artritt eller multippel sklerose.
NO972930A 1994-12-24 1997-06-23 Fibronectin-adhesjonsinhibitorer NO972930L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426254.0A GB9426254D0 (en) 1994-12-24 1994-12-24 Chemical compounds
GBGB9505905.1A GB9505905D0 (en) 1995-03-23 1995-03-23 Methods
GBGB9513904.4A GB9513904D0 (en) 1995-07-07 1995-07-07 Chemical compounds
PCT/GB1995/002992 WO1996020216A1 (en) 1994-12-24 1995-12-21 Fibronectin adhesion inhibitors

Publications (2)

Publication Number Publication Date
NO972930D0 NO972930D0 (no) 1997-06-23
NO972930L true NO972930L (no) 1997-08-19

Family

ID=27267539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972930A NO972930L (no) 1994-12-24 1997-06-23 Fibronectin-adhesjonsinhibitorer

Country Status (18)

Country Link
US (1) US6034056A (no)
EP (1) EP0800535A1 (no)
JP (1) JP3248584B2 (no)
CN (1) CN1171118A (no)
AU (1) AU705717B2 (no)
BR (1) BR9510284A (no)
CA (1) CA2204793A1 (no)
CZ (1) CZ198497A3 (no)
GB (1) GB9524630D0 (no)
HU (1) HUT77120A (no)
IL (1) IL116512A0 (no)
MX (1) MX9704767A (no)
NO (1) NO972930L (no)
NZ (1) NZ297530A (no)
PL (1) PL320995A1 (no)
SK (1) SK81097A3 (no)
TR (1) TR199501656A2 (no)
WO (1) WO1996020216A1 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6311996A (en) * 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
GB9613112D0 (en) * 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19653036A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Cyclopeptidderivate
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2003517023A (ja) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1423400B2 (en) * 2001-03-19 2013-05-22 President and Fellows of Harvard College Evolving new molecular function
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2002356180A1 (en) * 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
WO2007092471A2 (en) 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
EP2346865B1 (en) 2008-09-22 2015-07-15 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
BRPI0919881B1 (pt) * 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
PT2370442E (pt) 2008-11-26 2013-06-27 Pfizer 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
PE20120056A1 (es) 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
CA2793838C (en) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2661428B1 (en) 2010-12-23 2017-06-07 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
BR112013028430A2 (pt) 2011-05-04 2017-08-01 Merck Sharp & Dohme composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
GB201400292D0 (en) * 2014-01-08 2014-02-26 Haemostatix Ltd Peptide dendrimers and agents
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
EP3160959B1 (en) 2014-06-24 2023-08-30 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
WO2017059207A1 (en) 2015-10-01 2017-04-06 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
US11046695B2 (en) * 2015-11-11 2021-06-29 Zealand Pharma A/S Fragment synthesis of substituted cyclic peptides
CA3020594A1 (en) 2016-04-12 2017-10-19 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
JP2020501519A (ja) 2016-10-28 2020-01-23 ギンゴー バイオワークス， インコーポレイテッド 化合物の生産のための組成物および方法
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
KR20230079464A (ko) 2017-05-10 2023-06-07 질랜드 파마 에이/에스 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
EP3909952A4 (en) 2019-01-10 2023-01-25 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
SG52262A1 (en) * 1993-01-08 1998-09-28 Tanabe Seiyaku Co Peptide inhibitors of cell adhesion
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1996000581A1 (en) * 1994-06-29 1996-01-11 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
DE69516848T2 (de) * 1994-11-02 2000-12-07 Koninklijke Philips Electronics N.V., Eindhoven Wellenformerzeugung

Also Published As

Publication number Publication date
TR199501656A2 (tr) 1996-07-21
SK81097A3 (en) 1997-12-10
US6034056A (en) 2000-03-07
HUT77120A (hu) 1998-03-02
BR9510284A (pt) 1998-01-06
EP0800535A1 (en) 1997-10-15
PL320995A1 (en) 1997-11-24
GB9524630D0 (en) 1996-01-31
MX9704767A (es) 1997-10-31
CZ198497A3 (en) 1997-10-15
JP3248584B2 (ja) 2002-01-21
AU4269896A (en) 1996-07-19
NZ297530A (en) 2000-02-28
AU705717B2 (en) 1999-05-27
NO972930D0 (no) 1997-06-23
CN1171118A (zh) 1998-01-21
JPH10508315A (ja) 1998-08-18
CA2204793A1 (en) 1996-07-04
IL116512A0 (en) 1996-07-23
WO1996020216A1 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
NO972930L (no) Fibronectin-adhesjonsinhibitorer
Yaron et al. Proline-dependent structural and biological properties of peptides and proteins
ATE165836T1 (de) Peptide als arzneimittel
NZ332778A (en) Cyclic peptides that are cell adhesion inhibiting compounds that inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen and mucosal addressin cell adhesion molecule-1
FI102379B1 (fi) Uretaanisuojattuja aminohappo-N-karboksianhydridejä
DE3875538D1 (de) Aminoluciferine, verfahren zu deren herstellung und ihre verwendung.
DE69009476D1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
Witkop Chemical Cleavage of Proteins: Selective fragmentations and modifications reveal structure.
Katsoyannis The synthesis of the insulin chains and their combination to biologically active material
ABEL et al. Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses
Franciskovich et al. A systematic evaluation of the inhibition of HIV-1 protease by its C-and N-terminal peptides
KR0154528B1 (ko) 항응고성 펩티드
US5192747A (en) Anticoagulant peptides
JP3319771B2 (ja) 新規阻害性ペプチド類
ATE245168T1 (de) Peptide, die anti-zellanhaftungsaktivität aufweisen
US6159746A (en) Solid phase immunoassay to detect inhibitors of proteolytic enzymes
WO1993000108A1 (en) Novel inhibitors of platelet aggregation
Moroder et al. Studies on cytochrome c. Part I. Synthesis of the protected hexadecapeptide (sequence 1–16) of Baker's Yeast iso‐1‐cytochrome c
Ten Kortenaar et al. Semisynthesis of horse heart cytochrome c analogues from two or three fragments.
Wieland The history of peptide chemistry
Nozaki et al. Synthetic studies on troponin I active site. Preparation of a pentadecapeptide with inhibitory activity toward actomyosin adenosine triphosphatase
NO993684L (no) Peptider som omfatter et T-celle-epitop spesifikt til kollagen-II
ATE85077T1 (de) Enzym zur alpha-amidierung von c-termini und verfahren zu dessen herstellung.
ATE46173T1 (de) Pharmakologisch aktive peptide.
Leone et al. Characterisation of an epitope recognised by a monoclonal antibody against horse alcohol dehydrogenase using peptides synthesised on solid support

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application